Enedra Therapeutics appoints Dr Adrian Ibrahim as Chief Executive Officer
Enedra Therapeutics (Enedra), a pioneering biotechnology company focused on developing novel treatments for genetically heterogeneous cancers, today announced the appointment of Adrian Ibrahim, PhD, MBA, as its new Chief Executive Officer. Dr Ibrahim will also join the Company’s Board of Directors. His appointment comes as Enedra prepares to initiate its seed phase fundraising round.
Dr Ibrahim brings over 30 years of experience in the life sciences spanning academia and biotech with a proven track record as a company founder and executive leader. A strategic leader with deep expertise in company creation and technology commercialisation, Dr Ibrahim was the founding CEO of Mosaic Therapeutics, securing a US$28 million Series A investment from blue-chip investors and building the team that secured a clinical candidate within three years of first institutional investment. Prior to this, as Head of Technology Translation and Business Development at the Wellcome Sanger Institute for over a decade, he built the technology translation function, spun out multiple companies, and led the transaction that created the globally recognised Open Targets pharma consortium.
Dr Ibrahim said:
I am honoured and excited to lead Enedra Therapeutics at such a pivotal time, building on the amazing work of the founding team. The Company’s research and its CASPAROV platform hold incredible promise for patients suffering from difficult-to-treat cancers. My career has been dedicated to accelerating scientific breakthroughs into tangible healthcare benefits, and I am committed to advancing Enedra’s pipeline to bring these much-needed therapies to market.
Enedra’s upcoming seed phase funding round will support the advancement of its lead drug discovery programme through to in vivo proof-of-concept. The Company’s innovative platform technology is designed to target the underlying causes of cancer evolution and therapeutic resistance. Enedra already has high calibre backing and investment from Cancer Research Horizons, Deep Science Ventures, KU Leuven’s Centre for Drug Design and Discovery (CD3) and o2h Ventures.
Dr Andreas Ballis, Enedra’s co-founder and former CEO, will transition to the role of chief scientific officer, he said:
Adrian is the ideal leader to take Enedra to the next level. His combination of scientific knowledge and experience in biotech commercialisation will be invaluable as we prepare for our seed round and accelerate our research programmes. I look forward to working alongside him to realise Enedra’s vision of developing precision medicines for heterogeneous cancers.
